OCUL Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of 12.68%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat Boston Scientific Corp.'s return on equity of 12.55%.

Ocular Therapeutix, Inc. has a consensus price target of $25.67, signalling upside risk potential of 229.91%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.45%. Given that Ocular Therapeutix, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Ocular Therapeutix, Inc. is more attractive than Boston Scientific Corp..

Ocular Therapeutix, Inc. has a beta of 0.901, which suggesting that the stock is 9.856% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Ocular Therapeutix, Inc.'s net income of -$64.7M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 38.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 28.04x versus 5.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

EyePoint Plc has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of -6183.44%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat EyePoint Plc's return on equity of -79.15%.

Ocular Therapeutix, Inc. has a consensus price target of $25.67, signalling upside risk potential of 229.91%. On the other hand EyePoint Plc has an analysts' consensus of $36.33 which suggests that it could grow by 135.38%. Given that Ocular Therapeutix, Inc. has higher upside potential than EyePoint Plc, analysts believe Ocular Therapeutix, Inc. is more attractive than EyePoint Plc.

Ocular Therapeutix, Inc. has a beta of 0.901, which suggesting that the stock is 9.856% less volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.759%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are larger than EyePoint Plc quarterly revenues of $966K. Ocular Therapeutix, Inc.'s net income of -$64.7M is lower than EyePoint Plc's net income of -$59.7M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 28.04x versus 24.84x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of 21.74%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Ocular Therapeutix, Inc. has a consensus price target of $25.67, signalling upside risk potential of 229.91%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.58%. Given that Ocular Therapeutix, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.901, which suggesting that the stock is 9.856% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Ocular Therapeutix, Inc.'s net income of -$64.7M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 28.04x versus 5.90x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -487.96% compared to Ocular Therapeutix, Inc.'s net margin of 36.91%. Ocular Therapeutix, Inc.'s return on equity of -73.88% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Ocular Therapeutix, Inc. has a consensus price target of $25.67, signalling upside risk potential of 229.91%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.70 which suggests that it could grow by 11.28%. Given that Ocular Therapeutix, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ocular Therapeutix, Inc. has a beta of 0.901, which suggesting that the stock is 9.856% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Ocular Therapeutix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocular Therapeutix, Inc. quarterly revenues are $13.3M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Ocular Therapeutix, Inc.'s net income of -$64.7M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Ocular Therapeutix, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix, Inc. is 28.04x versus 10.19x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.